Lecture 6 Flashcards

1
Q

Antibody detection

A

key process in pretransfusion compatibility testing
ids in the detection and monitoring of patients who are at risks of delivering infants with hemolytic disease of the newborn (HDN) or hemolytic transfusion reactions (HTR) and immune hemolytic anemias

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the focus on antibody detection?

A

“irregular” or “unexpected” antibodies as opposed to the “expected” antibodies of the ABO system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Immune alloantibodies

A

produced in response to RBC stimulation through: transfusion, transplantation, or pregnancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Naturally occurring antibodies

A

produced without RBC stimulation
These antibodies may form because of exposure to environmental sources

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Passively acquired antibody

A

produced in another individual and then transmitted to the patient through plasma-containing blood products or derivatives such as intravenous immunoglobulin (IVIG) transfusions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What unexpected antibodies are great concern?

A

unexpected antibodies that cause decreased survival of the RBCs that possess the target antigens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

clinically significant antibodies

A

usually IgG antibodies, react at 37C or AHG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Autoantibodies

A

antibodies that are directed at the individual’s own RBC antigens
React with all cells tested

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Tube Technique

A

the traditional method of detecting antibodies is an indirect antiglobulin test (IAT) perform in a tube
2 drops patient’s serum or plasma is tested against 1 drop re-suspended O reagent RBCs with known antigens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are steps to the IAT?

A

4:
Immediate spin
thermal enhancement
AHG
CC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

IAT: IS phase

A

first phase of the test occurs in saline at room temperature
After centrifuging, the cell are examined for agglutination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Antibodies reacting below body temperature(37C) are?

A

considered cold antibodies
most cold antibodies are not clinically significant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

IAT: Thermal phase

A

second phase of the test, requires incubation at 37C
Following incubation, the tubes are centrifuged and examined for agglutination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

IAT: Antihuman globulin (AHG)

A

If thermal test is negative, proceed to AHG phase
Wash cells 3Xs and thoroughly pour off supernatant, Add AHG reagent, centrifuge, examine for agglutination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

IAT: CC

A

If AHG Test is negative, Add check-cell
All negative tubes should be positive when tested with check-cell
verifies AHG reagent viability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

RBC reagent

A

prepared from O cell individuals (anti-A and anti-B will not interfere in the detection of antibodies )
cells are suspended in 2%-5% concentrations of saline preservative (maintains the antigens and prevents hemolysis.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How many sets are needed for screening cells

A

packaged in sets of two or three cells with varied antigen expression
Within the set, there should be one cell that is positive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Screening cell antigens

A

Rh: D,C,c,E,e,Cw
Kell: K, k,
Duffy: Fya, Fyb
Kidd: Jka, Jkb
Lewis: Lea, Leb
MN: M, N, S, s,
Lutheran: Lua, Lub

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

homozygous antigen expression

A

an individual who inherited only one allele at a given locus.
Therefore, the cell surface has a double dose of that antigen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

heterozygous antigen expression

A

a person who inherited two different alleles at a locus
The alleles “share” the available antigen sites on the cellular surface

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Which is stronger: Heterozygous or homozygous dosage

A

Homozygous expression gives a stronger reaction than heterozygous expression

22
Q

Zeta Potentional

A

increasing the dielectric constant the cells drift closer together enabling antibodies to attach and agglutinate the cells

23
Q

Other potentiators:

A

22% albumin
Low Ionic Strength Solution (LISS)
Polyethylene Glycol (PeG)

24
Q

Albumin

A

reduces the zeta potential by decreasing the differences in the ionic layers surrounding the red cells
an increase in the dielectric constant

25
Q

LISS

A

lowers the zeta potential (increases the dielectric constant) and increases the uptake of antibodies onto the RBC

26
Q

PeG

A

a LISS solution
removes water from the test system - concentrating any antibodies present
can cause nonspecific aggregation of cells
more sensitive than LISS, albumin, or saline systems

27
Q

AHG reagent

A

allows for the agglutination of incomplete antibodies
contain anti-IgG

28
Q

Polyspecific AHG

A

contains antibodies to both IgG and complement components C3, and C4 or C3b and C3d

29
Q

Monospecific AHG

A

contains anti IgG only

30
Q

Screening Cells

A

Agglutination or hemolysis at any stage of testing is a positive test result: indicating the need for antibody identification studies

31
Q

Antibodies of the IgM class react

A

best at low temperatures and are capable of causing agglutination of the saline-suspended RBCs
anti-N, anti-I, and anti-P1

32
Q

Antibodies of IgG class react best

A

at the AHG phase
Rh, Kell, Kidd, and Duffy

33
Q

Autologous control

A

patient’s cells tested against the patient’s serum in the same manner as the antibody screen

34
Q

Autologous control: Test results

A

positive antibody screen + negative autologous control= an alloantibody has been detected
positive autologous control may indicate the presence of autoantibodies or antibodies to medications

35
Q

More than one screening cell sample may be positive when

A

the patient has multiple antibodies
when a single antibody’s target antigen is found on more than one screening cell or;
when the patient’s serum contains an autoantibody

36
Q

A single antibody specificity

A

suspected when all cells react at the same phase and strength

37
Q

Multiple antibodies

A

most likely when cells react at different phases and strength

38
Q

Rouleaux

A

characterized as stacked coins
dispersed with the addition of 2 to 3 drops of saline to the test tube
Serum from patients with: altered albumin-to-globulin ratios (Myeloma), high-molecular-weight plasma expanders

39
Q

Limitations of Screening tests

A

Cell to serum ratio: antibody is present in excess, false negative reactions occur
Length of Incubation:
PH: Optimum pH between 6.8 and 7.2

40
Q

Antibody Identification

A

Once an antibody has been detected, additional testing is required to identify the antibody(s) and to determine its clinical significance

41
Q

Patient History

A

Information concerning the patient’s age, sex, race, diagnosis, transfusion history, pregnancy history, medications, and intravenous solutions may provide valuable clues in antibody identification studies, especially with complex cases

42
Q

Antibody ID Panel

A

a collection of 11 to 20 group O cells with various antigen expression
pattern of antigen expression should be diverse enough that it will be possible to distinguish one antibody from another and should include cells with homozygous expression

43
Q

Exclusion/Rule-out Principle

A

first step is to exclude antibodies that could not be responsible for the reactivity seen
cells that gave a negative reaction in all phases of testing are examined
rule-out” technique only if the antigen is homozygously expressed on the cell

44
Q

inclusion technique

A

remaining antigens should be examined to see if the pattern of reactivity matches a pattern of antigen-positive cells

45
Q

DAT

A

used to detect in-vivo sensitization of RBCs

46
Q

Elution

A

used to release, concentrate, and purify antibodies
When IgG antibodies are detected, the next step is to dissociate them for identification

47
Q

Absorption

A

In cases where the coating antibody resists elution
RBCs to be phenotyped are incubated with diluted antiserum
The supernatant is harvested and tested against a cell with heterozygous antigen expression

48
Q

Absorption test results

A

if the patient’s cell is positive for the target antigen, the antibody will have been absorbed from the diluted antiserum
If the patient’s cells are negative for the target antigen, the antibody will remain in the antiserum

49
Q

Neutralization

A

In cases where the coating antibody resists elution
Other substances in the body and in nature have antigenic structures similar to RBC antigens
used to neutralize antibodies in serum, allowing for separation of antibodies or confirmation that a particular antibody is present

50
Q

Autoadsorption

A

Autoantibodies are commonly removed through adsorption techniques
The autologous cells are first washed thoroughly to remove unbound antibody
They may then be treated to remove any autoantibody coating the cells